TY - JOUR
T1 - When to Suspect Hidden Hypercortisolism in Type 2 Diabetes
T2 - A Meta-Analysis
AU - Aresta, Carmen
AU - Soranna, Davide
AU - Giovanelli, Luca
AU - Favero, Vittoria
AU - Parazzoli, Chiara
AU - Gennari, Luigi
AU - Persani, Luca
AU - Scillitani, Alfredo
AU - Blevins, Lewis S.
AU - Brown, David
AU - Einhorn, Dan
AU - Pivonello, Rosario
AU - Pantalone, Kevin M.
AU - Lunde Jørgensen, Jens Otto
AU - Zambon, Antonella
AU - Chiodini, Iacopo
N1 - Funding Information:
This work was partially supported by the Istituto Auxologico Italiano , Istituto di Ricovero e Cura a Carattere Scientifico (Grant 05C921 —PRECOR Study).
Funding Information:
This work was partially supported by the Istituto Auxologico Italiano, Istituto di Ricovero e Cura a Carattere Scientifico (Grant 05C921?PRECOR Study). C.A. is an investigator in studies on relacorilant (Corcept Therapeutics) in patients with hypercortisolism. L.S.B. serves as a consultant for Genentech/Roche. D.B. has received speaking and consulting fees from Corcept Therapeutics, Novo Nordisk, and Merck. D.E. has been a consultant for Corcept, Novo Nordisk, Eli Lilly, Abbott, Janssen, Boehringer Ingelheim, Epitracker, GlySens, and Intuity Medical and speaker bureau for Abbott, Novo Nordisk, Eli Lilly, and Boehringer Ingelheim and has received research support from Novo Nordisk, Eli Lilly, AztraZeneca, Mylan, and Teva. R.P. has received consulting fees from Corcept Therapeutics, HRA Pharma, Strongbridge, and Recordati Rare Diseases and is principal investigator in studies on relacorilant (Corcept Therapeutics), osilodrostat (Recordati Rare Diseases), levoketoconazole (Strongbridge), and metyrapone (HRA Pharma). K.M.P. reports being a member of the speaker bureau of AstraZeneca, Corcept Therapeutics, Merck, and Novo Nordisk and a consultant for AstraZeneca, Bayer, Corcept Therapeutics, Novo Nordisk, Merck, and Sanofi and has received research support from Bayer, Novo Nordisk, and Merck. I.C. is an investigator in studies on relacorilant (Corcept Therapeutics) in patients with hypercortisolism and received consulting fees from Corcept Therapeutics and HRA Pharma. D.S. V.F. C.P. L.Gi. L.Ge. L.P. A.S. J.O.L.J. and A.Z. have no multiplicity of interest to disclose.
Publisher Copyright:
© 2021 AACE
PY - 2021/12
Y1 - 2021/12
N2 - Objective: To investigate whether the available literature helps to identify the characteristics of patients with type 2 diabetes (T2D) more frequently associated with hidden hypercortisolism (HidHyCo). Methods: A meta-analysis was performed using studies that assessed both the prevalence of HidHyCo in patients with T2D and the characteristics of these patients with and without HidHyCo. The DerSimonian and Laird (DSL) and Hartung-Knapp-Sidik-Jonkman (HKSJ) methods were utilized. Results: Among the 18 available studies, 6 provided the necessary data. The association between HidHyCo and advanced T2D (based on the patients’ description given in each study in the presence of microvascular/macrovascular complications or insulin treatment plus hypertension or hypertension treated with 2 or more drugs), hypertension, insulin treatment, and dyslipidemia was reported in 5 (2184 patients), 6 (2283 patients), 3 (1440 patients), and 3 (987 patients) studies, respectively. HidHyCo was associated with advanced T2D as assessed by both the DSL (odds ratio [OR], 3.4; 95% confidence interval [95% CI], 2.12-5.67) and HKSJ (OR, 3.60; 95% CI, 2.03-6.41) methods and with the prevalence of hypertension or insulin treatment as assessed by the DSL method (OR, 1.92; 95% CI, 1.05-3.50 and OR, 2.29; 95% CI, 1.07-4.91, respectively) but not as assessed by the HKSJ method. Conclusion: Patients with advanced T2D have a higher prevalence of HidHyCo. These data inform about the selection of patients with T2D for HidHyCo screening.
AB - Objective: To investigate whether the available literature helps to identify the characteristics of patients with type 2 diabetes (T2D) more frequently associated with hidden hypercortisolism (HidHyCo). Methods: A meta-analysis was performed using studies that assessed both the prevalence of HidHyCo in patients with T2D and the characteristics of these patients with and without HidHyCo. The DerSimonian and Laird (DSL) and Hartung-Knapp-Sidik-Jonkman (HKSJ) methods were utilized. Results: Among the 18 available studies, 6 provided the necessary data. The association between HidHyCo and advanced T2D (based on the patients’ description given in each study in the presence of microvascular/macrovascular complications or insulin treatment plus hypertension or hypertension treated with 2 or more drugs), hypertension, insulin treatment, and dyslipidemia was reported in 5 (2184 patients), 6 (2283 patients), 3 (1440 patients), and 3 (987 patients) studies, respectively. HidHyCo was associated with advanced T2D as assessed by both the DSL (odds ratio [OR], 3.4; 95% confidence interval [95% CI], 2.12-5.67) and HKSJ (OR, 3.60; 95% CI, 2.03-6.41) methods and with the prevalence of hypertension or insulin treatment as assessed by the DSL method (OR, 1.92; 95% CI, 1.05-3.50 and OR, 2.29; 95% CI, 1.07-4.91, respectively) but not as assessed by the HKSJ method. Conclusion: Patients with advanced T2D have a higher prevalence of HidHyCo. These data inform about the selection of patients with T2D for HidHyCo screening.
KW - diabetes
KW - hypercortisolism
KW - hypertension
KW - insulin
UR - http://www.scopus.com/inward/record.url?scp=85119989363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119989363&partnerID=8YFLogxK
U2 - 10.1016/j.eprac.2021.07.014
DO - 10.1016/j.eprac.2021.07.014
M3 - Article
C2 - 34325041
AN - SCOPUS:85119989363
VL - 27
SP - 1216
EP - 1224
JO - Endocrine Practice
JF - Endocrine Practice
SN - 1530-891X
IS - 12
ER -